Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials

Cancer

Volumn 97, Issue 7, 2003, Pages 1663-1671

  Leibovich, Bradley C ^a,c   Blute, Michael L ^a   Cheville, John C ^a   Lohse, Christine M ^a   Frank, Igor ^a   Kwon, Eugene D ^a,b   Weaver, Amy L ^a   Parker, Alexander S ^a   Zincke, Horst ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Kidney; Metastasis; Neoplasms; Renal cell carcinoma; Survival

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALGORITHM; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER RESEARCH; CANCER SIZE; CANCER STAGING; CHILD; CLEAR CELL CARCINOMA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INFANT; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PATHOLOGICAL ANATOMY; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING HABIT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYMPTOMATOLOGY; TUMOR NECROSIS; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ALGORITHMS; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY;

EID: 0037379172     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11234     Document Type: Article

References (30)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Devesa SS, Silverman DT, McLaughlin JK, Brown CC, Connelly RR, Fraumeni JF Jr. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control. 1990;1:133-141.
3. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:987-989.
4. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-1623.
5. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
6. Mickisch GH, Garin A, van Poppel H, et al., for the European Organisation for Research and Treatment of Cancer. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
7. Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol. 2001;166:453-456.
8. Gelb AB. Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80:981-986.
9. Igarashi T, Tobe T, Nakatsu HO, et al. The impact of a 4 cm. cutoff point for stratification of T1N0M0 renal cell carcinoma after radical nephrectomy. J Urol. 2001;165:1103-1106.
10. Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol. 1999;162:1277-1281.
11. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995;154:35-40.
12. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
13. Papadopoulos I, Rudolph P, Weichert-Jacobsen K, Thiemann O, Papadopoulou D. Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. Urology. 1996;48:373-378.
14. Srigley JR, Hutter RV, Gelb AB, et al. Current prognostic factors - renal cell carcinoma: workgroup no. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:994-996.
15. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090-1095.
16. Zisman A, Pantuck AJ, Figlin RA, Belldegrun AS. Validation of the UCLA integrated staging system for patients with renal cell carcinoma. J Clin Oncol. 2001;19:3792-3793.
17. Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol. 2001;166:54-58.
18. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649-1657.
19. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002:421.
20. Frank I, Blute ML, Weaver AL, Zincke H. TNM staging alone is inadequate for predicting cancer-specific survival following radical nephrectomy for unilateral renal cell carcinoma. J Urol. 2001;165:768A.
21. Lau WK, Blute ML, Cheville JC. Pathologic stage T1 renal cell carcinoma: prognostic value of tumor subtype, size, and Fuhrman grade after radical nephrectomy. Urology. 2002;59: 532-537.
22. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89:604-614.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40:373-383.
24. Ward JF, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol. 2002;168:56-60.
25. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model, 1st. ed. Ann Arbor: Springer-Verlag, 2000.
26. Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol. 1990;144(2 Pt 1):238-241.
27. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
28. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with renal cell carcinoma of clear cell type treated by radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
29. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 1988;48(24 Pt 1):7310-7313.
30. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63-67.